Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2010

View Archived Issues

BNC-210 is well tolerated in healthy volunteers

AZ-004 is efficacious in preclinical model of inflammatory pain

Rivaroxaban is as effective as standard therapy in treating deep vein thrombosis

Oral JNJ-41876666 is active against cold allodynia in models of neuropathic pain

New glucagon receptor antagonists claimed by Merck & Co.

Abbott presents new inhibitors of GlyT-1

Shionogi recaps Q1 highlights of fiscal year 2010

New alpha2C-adrenoceptor agonists display antinociceptive effects and cardiovascular safety in vivo

Patient enrollment complete in Antisoma's phase III trial of AS-1413

BMS acquires ZymoGenetics and PEG-interleukin-29 for HCV infection

Transgene and Jennerex enter into exclusive partnership for JX-594

Sylentis to begin new phase I/II trial of SYL-040012 for elevated IOP and glaucoma

NeuroSearch discloses new voltage-gated potassium channel activators

GSK presents new dual histamine H1/H3 receptor antagonists

Merck & Co. discontinues development of MK-6913 for hot flashes

Taisho Pharmaceutical claims new selective SGLT1 inhibitors

N30 Pharma begins dosing in first-in-human phase I trial of N-6022

FDA advisory committee recommends approval of ceftaroline fosamil for CABP and cSSSI

Cempra begins studies of oral and intravenous solithromycin

Phase III trial begins of oral methylnaltrexone in opioid-induced constipation

FDA approves expanded indications for Saphris

Condition for approval removed for Avastin in Japan

Mylan acquires Bioniche Pharma ahead of schedule

Emergent BioSolutions begins phase I trial of inhalational anthrax treatment

FDA approves Abbott RealTime HBV assay

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...